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1. Introduction 
The World Health Organization (WHO) estimates that 84 million people will die of  
cancer between 2005-2015 [1]. According using the WHO mortality database it has been 
estimated the total number of cancer deaths in the European Union (EU) and in 2012 is 
predicted to be 1283101, of which 717398 men and 565703 women [2]. The most common 
types of cancer that will be diagnosed are lung (C33-C34), intestine (colon and rectum; C18-
C21) and prostate (C61) for men, and breast (C50), intestine (C18-C21) and lung (C33-C34) 
for women. 
Cancer is a group of diseases which cause an abnormal and uncontrolled cell  
division coupled with malignant behavior such as invasion and metastasis [3]. A tumor 
malignant is a neoplasm characterized by a failure in the regulation of tissue growth. The 
abnormal proliferation of tissues is caused by mutations of genes (oncogenes that promote 
cell growth and reproduction, and tumor suppressor genes that inhibit cell division and 
survival). Typically, changes in many genes are required to transform a normal cell into a 
cancer cell. 
It is necessary to improve our knowledge of cancer physiopathology for effective cancer 
therapy, which will allow discover new anti-cancer drugs and develop novel biomedical 
technologies. The benefits of traditional chemotherapy are limited by the toxicity associated 
with anticancer drugs in healthy tissues. The common features of cancer and healthy cells 
make it difficult to achieve pharmacoselectivity of drugs at the target site.  
The development of drug delivery systems that are able to modify the biodistribution, tissue 
uptake and pharmacokinetics of therapeutic agents is considered the great importance in 
biomedical research and the pharmaceutical industry. Controlled release in drug delivery 
can significance enhance the therapeutic effect of a drug. A constant concentration of a drug 
over an extended period of time keeping the drug concentration within the optimum range, 
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or a pulsatile drug release in response to an environmental change, can be achieved with 
controlled drug delivery systems [4]. In these type of systems, the drug is protected from 
degradation following administration, the delivery system can be administered close to the 
tumoral cells, the drug is released with a specific patron and the action of the drug on 
tumoral cells can be direct. 
Nanotechnology, refers to the understanding and control of matter at dimensions  
between approximately 1 and 100 nanometers in at least one dimension. Nanomaterials 
have a large surface area to volume ratio and their biological and physicochemical 
properties, such as friction and interaction with other molecules, are distinct  
from equivalent materials at a larger scale. These new properties open opportunities in a 
wide variety of areas of technology, ranging from intelligent nanoscale materials to 
medicine and biology, where first nanotechnology applications have demonstrated  
an enormous potential [5]. Thus, the term nanomedicine has been taking shape and has 
been defined as the applications of nanotechnology for treatment, diagnosis, monitoring 
and control of biological systems by the National Institutes of Health [6]. Nanomedicine 
attempts to use sophisticated approaches to either kill specific cells or repair them one  
cell at a time, offering new possibilities towards the development of personalized 
medicine [7] focused on certain diseases which are currently being investigated, especially 
cancer. 
One of the most important and hopeful tools employed in nanomedicine are nanoparticles 
(NPs), which are solid, colloidal particles consisting of macromolecular substances that 
are being developed to: improve drug bioavailability, abrogate treatment-induced drug 
resistance, and reduce nonspecific toxicity in the field of medicine. Depending on the 
method of preparation NPs can be constructed to possess different properties and release 
characteristics for the best delivery or encapsulation of the therapeutic agent [8]. In all 
these types, drugs can be absorbed onto the surface, entrapped inside, or dissolved within 
the matrix of the NPs [9]. One advantage of NPs is their ability to overcome various 
biological barriers and to localize into the target tissue. The first generation of NPs 
comprises passive delivery systems that, in case of cancer, reach the tumor through the 
fenestrations in the adjacent neovasculature [10]. The unique mechanism of driving 
systems to the tumor site is the nanometer size of particles, not specific recognition of the 
tumor or neovascular targets.  
In order to optimize the therapeutic index of antitumor drugs, decreasing their toxicity  
to normal tissues, a second generation of nanosystems includes additional functionalities 
that allow for molecular recognition of the target tissue or for active or triggered release  
of the payload at the disease site. Thus, the presence of reactive pendant groups in  
NPs make easy their vectorization forward specific cell motif by binding of ligands. These 
include various ligands [11-13] that bind to specific target cell surface markers  
or surfacemarkers expressed in the disease microenvironment. Responsive systems,  
such as pH-sensitive polymers, are also included in this category. Hence, over the past 
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years, efforts have been focused on the development of nanomedicines such as NPs, 
liposomes, micelles or dendrimers for the specific delivery of anticancer drugs to tumor 
tissues [14].  
2. Physiological characteristics of solid tumors 
Tumors are characterized by poorly differentiated, highly chaotic arrangement of vessel 
which have endothelial cell-cell junctions and discontinuous basement membrane. 
Angiogenesis is not only a prerequisite for the transformation from a small, often dormant 
cluster of cancer cells to a solid tumor, but is also required for the spread of tumor. 
Microvascular network is absolutely essential for the development of solid tumors. Once a 
tumor cell cluster, whether in its initial stage as a primary tumor or in later stages when 
forming metastases, induces an angiogenic switch, its vasculature and microenvironment 
changes dramatically, and abnormal cellular organization, vessel structure, and physiology 
function develops (Figure 1). Angiogenesis is defined as the formation of new blood vessels 
from existing ones. For solid tumors of 1-2 mm3, oxygen and nutrients can reach the center 
of the tumor by simple diffusion. Because of their non-functional or non-existent 
vasculature, non-angiogenic tumors are highly dependent on their microenvironment of 
oxygen and the supply nutrients. When tumor reaches 2 mm3, a state of cellular hypoxia 
begins, initiating angiogenesis.  
Angiogenesis is regulated by a fine balance of activators and inhibitors [15]. The vascular 
endothelial grown factor (VEGF), also called vascular permeability factor (VPF), plays an 
important role in regulating the process of tumor angiogenesis. VEGF has been shown to 
stimulate the proliferation, migration and invasion of endothelial by interacting with a 
family of tyrosine kinase receptor expressed on vascular endothelium. VEGF is also known 
to have the ability to enhance the permeability of microvessels, favoring the rapid and 
reversible increases in extravasation of plasma protein in tissue [16]. In the angiogenesis 
process, different phases can be distinguished: Dilation of existing vessels, endothelial cell 
activation, migration and proliferation, hyperpermeability of postcapillary venules and 
vessel destabilization, basement membrane degradation by proteases such as matrix 
metalloproteases, cathepsines, urokinase and plasmin, endothelial cell migration, vessel 
formation and angiogenic remodeling [17]. 
The new tumor vessels formed during angiogenesis differ markedly from those of normal 
tissues and the neovasculatures is characterized by an irregular shape, high density, and 
heterogeneity, and also have different oxygenation, perfusion, pH and metabolic states. 
The abnormal vascular architecture plays a mayor role for an EPR (Enhanced 
Permeability and Retention) effect [18]. Extensive angiogenesis and hypervasculature, 
lack of smooth-muscle layer, pericytes, defective vascular architecture: fenestrations, no 
constant blood flow and direction, inefficient lymphatic drainage that leads to enhanced 
retention in the interstitium of tumor and slow venous return that leads to accumulation 
from the interstitium of tumor. 
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Physiological changes in blood flow within the tumors and in transport properties of tumor 
vessels are consequences of these vascular abnormalities. The osmotic pressure in tumors is 
high [19]. The interstitial compartment of tumors is significantly different to that of normal 
tissues. Primarily, as a result of vessel leakiness and hyperpermeability with a concomitant 
bulk flow of free fluid into the interstitial space that cannot be removed effectively due to a 
lack of functional lymphatics, due to cancer cells compress lymphatic vessels causing their 
collapsed. The lymphatic network transports interstitial fluid and immune cells out of 
normal tissue and is essential for immune function and maintenance of fluid balance in 
tissue interstitium. In tumor cells the vessels are compressed by solid stresses. The function 
of lymphatic vessels depends on their localization, when they are at the periphery of the 
tumor or the periphery tumor interface possesses functionality, while those within the 
tumor are functionality defective. VEGF factors (VEGF-C and VEGF-D) and their 
corresponding receptors have been identified as specific lymphangiogenesis factors in 
several tumors, and have been implicated in increased lymphatic metastases in numerous 
tumors [20].  
 
Figure 1. Differences between healthy and tumor tissues. A) Healthy tissue is characterized by a good 
flow in blood vessel. These vessels are supported by pericytes with a good physiological organization 
and structure. They provide adequate amounts of glucose and oxygen to normal cells. Collagen fibres, 
fibroblasts and macrophages are present in the extracellular matrix. Lymph vessels are present and 
allow the elimination of waste products. B) Tumoral tissue is characterized by vascular disorganization, 
with fenestrations and discontinuous basement membrane, that promotes the metastasis of abnormal 
cells to other tissues, inadequate supply of nutrients and poor lymphatic network that does not drain 
properly increasing the amount of waste products in these tissues and also increasing the protons 
concentration which decrease the physiological pH. Components of extracellular matrix (collagen fibres, 
fibroblasts and macrophages) in this type of tumor tissue are also increased 
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Leaky tumor vasculature and dysfunctional lymphatics in tumor interstitium result in 
undesirable accumulation of vascular contents in the tumor leading to interstitial 
hypertension [19]. In normal tissues the interstitial fluid pressure (IFP) is approximately 0 
mm Hg, and the pressure in the capillary is around 1-3 mmHg, this gradient facilitates the 
transport of macromolecules. In tumor tissues the pressure gradient is contrary, 
consequently, interstitial hypertension results in reduce convection across the walls of 
tumor blood vessels. IFP tends to be higher at the center of solid tumors, diminishing 
toward the periphery, creating a mass flow movement of fluid away from the central region 
of tumor. The microvasculature pressure in tumors is also one to two orders of magnitude 
higher than in normal tissues.  
Abnormal tumor vasculature reduces blood flow and limit delivery of oxygen throughout 
the tumor resulting in regions of hypoxia. There are different types of hypoxia: 
inadequate perfusion (ischemia), increased diffusion distance (chronic hypoxia), anemia 
and hypoxemia [20]. The hypoxic condition initiates signaling events that trigger  
the upregulation of multiple pro-angiogenic factors in the tumor lesion, another 
consequence, the lack of oxygen promotes an anaerobic metabolism of tumor cells and an 
extracellular acidosis in tumor tissues, primarily due to excessive production of lactic acid 
and CO2 [20].  
So, while the intracellular pH of cells within healthy tissues and tumors is similar, tumors 
exhibit a lower extracellular pH than normal tissues. Accordingly, although tumor  
pH may vary according to the tumor area, average extracellular tumor pH is between 6.0 
and 7.0, whereas in normal tissues and blood the extracellular pH is around 7.4 [21-22]. 
Low pH and low pO2 are intimately linked and a variety of insights now support their 
roles in the progression of tumor from in situ to invasive cancer [23]. The low extracellular 
tumor pH mostly arises from the high glycolysis rate in hypoxic cancer cells. However, 
ATP hydrolysis, glutaminolysis, and ketogenesis also contribute to this extracellular 
acidic pH.  
Therefore, due to the cancer cell presents differences compared to normal cell including 
vascular abnormalities, interstitial pressure, oxygenation, pH, metabolic states, and 
abnormal lymphatics, a preferential accumulation of encapsulated drug at desired sites can 
be obtained either by passive or active targeting. 
3. Targeted drug delivery nanoparticles 
Targeted NP therapeutics have shown great potential for cancer therapy, as they provide 
enhanced efficacy and reduced side effects [24]. NP drug delivery can be either an active or 
passive process. Passive delivery refers to NP transport through leaky tumor capillary 
fenestrations into the tumor interstitium and cells by passive diffusion or convection [25]. 
Selective accumulation of NP and drug then occurs by the already mentioned characteristics 
of the tumor microenvironment (Figure 2).  
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Figure 2. NPs are more able to reach tumor cells through passive targeting due to the characteristics of 
tumor tissue (vascular disorganization, fenestrations, discontinuous basement membrane, etc.). In 
normal tissues the lower amount of nanoparticles that able to reach it are removed by lymph vessels 
while, in tumor tissues, lymphatic network is too damaged to perform its function promoting the 
accumulation of nanoparticles in the tissue. The functionalized nanoparticles are internalized not only 
by passive targeting but also by active targeting. This active targeting is more effective in the tumor 
tissue due to tumor cells overexpress some receptors that allow them a better uptake of functionalized 
nanoparticles. 
Active targeting involves drug delivery to a specific site based on molecular recognition. 
One such approach is to couple a ligand, such monoclonal antibodies, lectins, aptamers, 
folate, and peptides, to a NP so that the ligand can interact with its receptor at the target 
cell site (Figure 2). Depending on the type of ligand-receptor interaction, the rate of 
cellular internalization would differ. This is an important factor as rates of internalization 
could affect the accumulation of NP in tumor sites. The use of a targeting moiety also 
facilitates cellular uptake of the drug by receptor mediated endocytosis, which is an active 
process requiring a significantly lower concentration gradient across the plasma 
membrane than simple endocytosis. Thus there is plenty of room to improvise these 
systems to address the above-mentioned issues and different groups are working to 
improve the targeting properties of NPs and for the development of targeted therapeutics 
[26]. In table 1 are shown various nanocarriers evaluated to deliver therapeutic agents into 
cancer cells.  
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Ligand Nanosystem Drug Cell/tumor model Reference 
AS1411 DNA apt 
nucleolin /liposomes cisplatin MCF-7 [27] 
PEG-PLGA NPs PTX C6 glioma cells [28] 
Sgc8c apt SWNTs Dau 
acute lymphoblastic 
leukemia T-cells 
(Molt-4). 
[29] 
Thrombin apt Mesoporous silica NP Dtxl HeLA cells [30] 
EGF SWNTs Cisplatin HNSCC [31] 
antiHER-2 ab: 
Trastuzamab 
PLGA/MMT NPs PTX breast cancer [32] 
Tf 
PLA-PEG NPs PTX 
BT4C rat glioma 
model 
[33] 
PLGA–NPs PTX 
C6 glioma cells 
PC3 Prostate cancer 
cell 
[34] 
G4 PAMAM dendrimers Dox, C6 glioma cells [35] 
FA 
G5 PAMAM dendrimers MTX 
human KB tumor 
xenografts 
[36] 
PEG liposomes Dox KB cells [37] 
NIPA-NPAM-2AAECM
5-FU, 
TMX 
T47D cells, HeLa 
cells 
[38] 
cRGD PEG-PTMC micellar NPs PTX U87 MG cells [39] 
Antiαv integrin ab HSA NPs Dox Melanoma cells [40] 
Table 1. Examples of nanocarriers used for active targeted drug delivery 
3.1. Aptamers 
Originally discovered in 1990, aptamers are short nucleic-acid-based single stranded ligands 
(DNA, RNA, oligonucleotide), whose size could vary from 20 to 80 nucleotides [27,41], that, 
through intramolecular interactions, fold into unique tertiary conformations capable of 
binding to target proteins with high affinity (KD=10 pmol/l to 10 µmol/l) and specificity. This 
property makes them an attractive class of targeting molecules as they are also 
nonimmunogenic and exhibit remarkable stability. Aptamers can tolerate a moderate 
change in temperature, pH (4-9), and ionic strength, and can be processed with organic 
solvents without a lost of activity [13]. Aptamers are chemically synthesized and they 
possess additional advantages over natural antibodies [42] including a smaller size, and 
single-chain variable fragment antibodies what allows for more efficient penetration into 
biological compartments [43] and due to which they accumulate quickly within the tumor 
tissue. It is possible to chemically modify aptamers to facilitate covalent conjugation to 
nanomaterials, for example, with 50 or 30 amino or thiol groups. These properties in 
aptamers enable them to withstand the common production conditions encountered during 
NP preparation. However, due to this small size, aptamers can be cleared quickly by the 
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kidneys. To delay their clearance, polyethylene glycol (PEG) or cholesterol can be added to 
aptamer NPs [44-45]. Aptamers that are internalized by cells can be used to study 
internalization pathways or used as drug targeting agents [24].  
Traditionally, a number of compounds were assayed to isolate a ligand for the production of 
aptamers. However, development of a technique called ‘in vitro selection’ or Systematic 
Evolution of Ligands by Exponential Enrichment (SELEX) has allowed the rapid and 
selective production of aptamers. Briefly, the SELEX method starts with a random library of 
1013–1016 single-stranded DNA or RNA and uses an iterative process that specifically 
amplifies sequences that have high binding affinity to the target molecules [46-47]. Although 
many complex forms of SELEX exist, there are two basic forms of SELEX (Cell-SELEX and 
Automated SELEX) [41]. 
Aptamers can be designed as targeting ligands, and can differentiate diseased cells from 
healthy cells, thus enabling the selective delivery of therapeutic compounds to target cells 
[41,47]. A large number of aptamers have been raised against cancer-associated antigens 
such us AS1411 aptamer for targeting nucleolin protein, which is highly expressed in the 
membrane of cancer cells [48-49], aptamers CPG 7909 and IMO 2055, that target Toll-like 
receptor 9 (TLR9), which is expressed by certain immune cells, TD05 aptamer, which was 
selected for the Burkitt’s lymphoma Ramos cell line [47], Sgc8c aptamer which targets 
leukemia biomarker protein tyrosine kinase-7 (PTK7) [46,50] and can recognize target 
leukemia cells, DNA aptamers to leukemic lymphoid (CEM) cells [46], and 
fruoropyrimidine RNA aptamers which target Prostate-specific membrane antigen (PSMA) 
[51] for targeting prostate cancer. And also another aptamers against antigens such as 
pigpen [52] for targeting the tumor microvasculature, or mucin 1 (MUC1) [53] for targeting 
various epithelial neoplasms that upregulate MUC1, whose expression has been associated 
with carcinomas. 
Aptamer-functionalized NPs have also been widely used for cancer cell specific drug 
delivery. Aptamers that were conjugated to NPs resulted in increased targeting and more 
efficient therapeutics, as well as more selective diagnostics. For instance, it has been 
synthesized NPs of poly(D,L-lactide-coglycolyde) [PLGA] and PEG triblock copolymer 
using aptamers as a targeting ligand for PSMA and Docetaxel (Dtxl)-encapsulated 
demonstrated that they bind and are taken up by LNCaP prostate ephitelial cells resulting in 
a significantly enhanced in vitro cellular toxicity as compared with nontargeted NP [24]. In 
the same way A10 aptamer is being explored for the targeted delivery of several anticancer 
agents, by including paclitaxel (PTX) and cisplatin in NPs [51,54]. Guo and coworkers 
conjugated DNA aptamers to a PEG-PLGA NP as a novel drug delivery system capable of 
targeting cancer cells and endothelia cells in angiogenic blood vessels [28]. In the tested C6 
glioma cells, aptamer-nucleolin specific binding resulted in the cellular association of NPs 
and thereby enhanced the cytotoxicity of the PTX delivery. They suggested the potential of 
utilizing Ap-PTX-NP as therapeutic drug delivery platform for gliomas treatment [28].  
Besides organic NPs, inorganic systems of Au-Ag nanorods (NRs) were synthesized to serve 
as a platform for binding several aptamer molecules. Thus, Au-Ag NRs have been 
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conjugated with multiple anti-PTK7 aptamers, such as scg8 aptamer, for targeted cancer 
photothermal therapy [48,55]. By using Au-Ag NRs that can be conjugated around 80 
aptamers, 26 times higher binding affinity was obtained compared to individual aptamer 
strands [48]. By functionalizing the surface of Au NPs with an RNA aptamer that binds to 
PSMA, NP–aptamer conjugates were used for targeted molecular computed tomography 
imaging and treatment of prostate cancer [56].Yin et al. reported a one-step method for the 
synthesis of DNA-aptamer templated fluorescent silver nanoclusters (AgNCs) [57]. The 
Sgc8c aptamer strands were immobilized onto AgNCs through cytosine-rich sequence, and 
the resulting Sgc8c-modified AgNCs showed specific targeting to CCRF-CEM cancer cell 
over control cells.  
In addition to their ability to recognize a target molecule with high specificity, certain 
aptamers can also modulate the activities of proteins implicated in pathological conditions, 
making aptamers potentially useful as pharmaceutical agents. For instance, one of the most 
important success of aptamers so far has been the development of aptamers that are able to 
bind VEGF [58] such as Pegaptanib sodium aptamer (Macugen, Pfizer, and Eyetech). 
However, as aptamers are expensive to produce, it is more economical to use aptamers as 
targeting agents rather than as therapeutic agents. Another example is AS1411, that binds 
specifically to nucleolin, a bcl-2 mRNA binding protein involved in cell proliferation, which 
is found on the surface of many cancer cells. Once bound, the AS1411 aptamer is taken into 
the cancer cell, where it causes death by apoptosis [47,59].  
Furthermore, antidotes for anticancer agent toxicities are of interest to regulate drug activity. 
Thus, aptamers can also be prepared as antidotes for anticancer drugs to modulate 
anticancer effects. In this way, cDNA aptamer was recently designed for inhibiting cisplatin 
activity. The multifunctional carrier system consisted of cisplatin as the anticancer agent, 
which was encapsulated within a liposomal system and conjugated to AS1411-derived 
aptamer. In the absence of cDNA, the targeted NP showed cell-specific targeting and an 
improved cytotoxicity. When de cDNA aptamer was administered, it inhibited the cytotoxic 
activity of cisplatin. However, the interval between the administration of cDNA and NP 
seemed to be critical [11,27]. 
3.2. Human epidermal receptor 
The Human epidermal receptor (HER)-family tyrosine kinases play a central role in the 
proliferation, differentiation, and development of cells as they are known to mediate a cell 
signaling pathway for growth and proliferation in response to the binding of the growth 
factor ligand [60]. The family consists of four members: epidermal growth factor receptor 
(EGFR or HER1), HER2 (also known as ERBB2 or HER-2/neu), HER3 and HER4. Each of 
these receptors has an extracellular region, a single transmembrane region, and a 
cytoplasmic sequence containing a tyrosine kinase domain and a C-terminal tail [61]. 
EGFR has six known endogenous ligands: EGF, transforming growth factor-α (TGF-α), 
amphiregulin, betacellulin, heparin-binding EGF (HB-EGF), and epiregulin [60]. Using any 
of these ligands as targeting moieties offers a method for targeting the EGFR; especially 
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TGF-α and EGF as are the most commonly detected in humans. Ligand binding to EGFR 
results in activation of intracellular signaling cascades in cancer cell proliferation, apoptosis, 
migration, sensitivity to chemoradiation therapy, and tumor angiogenesis, and the complex 
is internalized for destruction and recycling [12, 62-63]. Over one-third of all solid tumors 
have been shown to express EGFR, and in many of these tumors, EGFR expression 
characterizes a more advanced disease stage [60]. The presence of EGFR corresponds 
directly to the metastatic capabilities in various types of cancer, such as colorectal [12]. 
Among the wide range of tumors that overexpress EGFR are breast, lung, colorectal, 
pancreatic cancers [63], glioblastomas [64], and brain cancers [65].  
Hence EGF target delivery systems have been used in cancer molecular imaging diagnosis 
and therapy [63]. Thus, cisplatin and EGF were attached to single-wall carbon nanotubes 
(SWNTs) to target squamous cancer cells HNSCC which overexpress EGFR. Through Qdot 
luminescence and confocal microscopy, it was shown that SWNT–Qdot–EGF bioconjugates 
was rapidly internalized into the cancer cells, and HNSCC cells were selectively killed in 
vitro, while tumor growth was regressed in vivo [31]. A current cancer treatment that 
targets EGFR is the monoclonal antibody Cetuximab, which targets the extracellular domain 
of EGFR and small-molecule inhibitors of tyrosine kinase activity [66]. One study showed 
that boronated immunoliposomes with conjugated Fab′ fragments of Cetuximab mAb 
delivered ~8 times more boron to EGFRpositive cells (F98EGFR) than non-targeted IgG 
immunoliposomes [67].  
With regard to HER2, among tumor biomarkers the HER2 membrane receptor is one of the 
most promising targets for immunotherapy. The surface accessibility, the high level of 
expression in certain primary and metastatic tumors and the internalization of these 
antigens via receptor-mediated endocytosis [68] promote preferential intracellular 
accumulation of drug nanocarriers [69]. The gene encoding HER2 protein is present in 
normal cells as a single copy and is expressed at low levels in many normal epithelial cells. 
Amplified HER2 gene and its over-expressed protein product are found in many types of 
cancers, including breast, ovary, lung, pancreas [63,70], stomach and renal. The 
overexpression of HER2antigens (c-erbB-2, neu) in 20–30% of breast and ovarian cancers is 
correlated with a high occurrence of metastasis and angiogenesis processes, as well as with a 
poor prognosis [71]. The ligand binding to the extracellular domain of HERB2 causes the 
dimerization of the receptor and in this way the activation of many intracellular signaling 
proteins and physiological pathways, such as the mitogen-activated protein kinases (MAPK) 
pathway, phospahtidylinositol 3-kinase/AKT/mTOR pathway, and Src tyrosine kinase [61]. 
Thus, antibodies and antibody fragments, consisting of only the Fab binding regions, against 
the HER2 receptor are common examples of receptor targets. These antibodies generally 
exhibit strong interactions with corresponding receptors, with dissociation constants in the 
nanomolar range. The advantages of the antibody fragments is that they are smaller, and do 
not contain the Fc region of the antibody which can induce immunogenicity and antigenicity 
[72]. Antibody-labeled NP is one of the most coveted modes of active targeting of NPs. 
Blocking the activity of the upregulated receptor by binding it with a ligand, such as 
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monoclonal antibody (mAb) represented on the nanovector, would ensure arrest of the 
signalling pathway(s).  
Anti-Her2 mAbs (trastuzumab; Herceptin®), a humanized mAb designed to specifically 
antagonize HER2 function, was approved in 1998 for metastatic breast cancer 
overexpressing HER2 antigens [70]. Hence Herceptin® is used as a targeting moiety for 
various NP systems. For instance, incorporation of anti-HER2 antibodies onto the surfaces of 
PEGylated liposomes has indeed shown greater efficiency for drug delivery compared to 
non-targeted PEG-liposomes [73] and significantly higher intracellular accumulation was 
observed with targeted liposomes in xenografts of the HER2 overexpressing BT-474 tumors 
compared to MCF-7 tumors [69]. It has also been used PTX-loaded anti-HER2 
immunonanoparticles (NPs-PTX-HER) which were prepared by the covalent coupling of 
humanized monoclonal anti-HER2 antibodies (trastuzumab, Herceptin®) to PTX-loaded 
poly (DL-lactic acid) NPs (NPs-PTX) for the active targeting of tumor cells that overexpress 
HER2 receptors [71]. NPs-PTX were thiolated and conjugated to activated anti-HER2 mAbs 
to obtain immunonanoparticles. The immunoreactivity and the in vitro efficacy of NPs-PTX-
HER were tested on SKOV-3 ovarian cancer cells that overexpress HER2 antigens and it was 
demonstrated the greater cytotoxic effect of NPs-PTX-HER compared to other PTX 
formulations. Lyu and coworkers [74] used a single-chain Fv antibody (scFv23) targeting 
HER-2/neu to deliver tumor necrosis factor (TNF) to TNF-resistant pancreatic cancer cells 
and compared the cell responses to TNF alone, scFv23/TNF, herceptin, and combinations of 
scFv23/TNF with various chemotherapeutic agents including 5-Fluorouracil (5-FU), 
cisplatin, doxorubicin (Dox), gemcitabine, and etoposide. Their results indicated that 
delivery of TNF to HER2/neu-expressing pancreatic cancer cells using HER2/neu as a 
targeting molecule may be an effective therapy for pancreatic cancer especially when 
utilized in combination with 5-FU. 
3.3. Transferrin receptor 
Transferrin (Tf) (Mw=80 kDa) is the fourth most abundant serum nonheme iron-binding 
glycoprotein. It is synthesized by the liver and secreted to plasma, where it binds to 
endogeneous iron, forming the iron-transferrin chelate which is an important physiological 
source of iron for cells in the body. It helps to transport iron to proliferating cells [75], which 
is required as a cofactor for DNA synthesis [76], and it also plays a pivotal role in the 
transportation of iron for the synthesis of hemoglobin. Based on these facts, Tf can be 
potentially utilized as a cell marker for tumor detection. 
Normally at a cell, Tf offloads the iron onto a transferrin receptor (TfR). The natural ligand 
for TfR, Tf, binds to its receptor with a dissociation constant of around 40nM. TfR, also 
known as CD71, is a dimeric transmembrane glycoprotein (180 kDa) [77]. The receptor for 
Tf, referred to as TfR1, is ubiquitously expressed at low levels in most normal human 
tissues. A second member of the TfR family is TfR2, a protein that is homologous to TfR1 
but whose expression is largely restricted to hepatocytes [76]. This receptor is an attractive 
molecule for the targeted therapy of cancer since it is upregulated on the surface of many 
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cancer types and is efficiently internalized. Serving as the main port of entry for iron bound 
Tf into cells, TfR1 is a type-II receptor that resides on the cell membrane and cycles into 
acidic endosomes into the cell in a clathrin/dynamin dependent manner [78]. The low pH 
environment triggers dissociation of the iron and the iron-poor Tf is released out of the cell 
for recycling. As cancer cells rapidly proliferate, the TfR is overexpressed in the surface of 
malignant cells due to the increased requirement of iron [12]. In this sense, many studies 
have indicated that the expression level of TfR on tumor cells is much higher than that on 
normal cells [79], such as the surface of cerebral endothelium and brain tumor cells [80], 
breast cancer, prostate cancer, and squamous cell carcinomas [63]. This enhanced TfR 
expression, at levels correlating with the grade of malignancy [81], can be exploited for 
actively delivering anticancer agents specifically to tumor tissues. This receptor can be 
targeted in two ways: 1) for the delivery of therapeutic molecules into malignant cells or 2) 
to block the natural function of the receptor leading directly to cancer cell death [78]. 
A wide variety of therapeutic agents have been used for TfR-targeted cancer therapy. They 
include chemotherapeutic drugs, bacterial toxins, plant toxins, DNA, oligonucleotides, short 
inhibitory RNA (siRNA), and enzymes. Vast types of anti-cancer drugs that have been 
delivered into cancer cells employing a variety of receptor binding molecules including the 
use of its natural ligand Tf, anti-TfR antibodies, or TfR-binding peptides alone or in 
combination with carrier molecules including NPs and viruses [78].  
With regard to NPs, Tf has a number of properties that allow it to be successfully 
incorporated as a targeting ligand in NP systems, such as its stability over a wide pH range 
(3.5-11) and that has shown to be unaffected by repeated freeze-thaw cycles; hence, it can be 
subjected to processing conditions commonly encountered during NP preparation [11]. 
Furthermore, Tf is available in recombinant version (Optiferrin) [82] and, as a human 
protein, has low immunogenicity [83]. Normally, Tf can be conjugated to NPs less than 100 
nm in size to obtain an enhanced cytotoxic activity. If the NPs are greater than 100 nm, it 
may lead to poor accumulation of these NPs in the tumor cells, which results in moderate 
anticancer activity. To overcome this issue, the actively targeted system can be directly 
administered into the tumor tissue by intratumoral injection [84]. 
Tf-conjugated NPs have been explored in a number of studies for the delivery of anticancer 
agents. Thus, gold NPs were conjugated with Tf molecules for targeting, imaging and 
therapy of breast cancer cells (Hs578T, ATCC), showing that, the Tf–TfR-mediated cellular 
uptake of gold NPs is six times of that in the absence of this interaction [85].  
It has also been [86] prepared PTX loaded NPs with shells formed of the biodegradable 
polymer, PLGA, conjugated to Tf via epoxy linkages. The Tf-conjugated NPs demonstrated 
greater cellular uptake and reduced exocytosis, yielding greater antiproliferative activity 
and more sustained effects compared to the free drug or unconjugated NPs. In a similar 
way, particulate nanodrugs consisting of PLGA loaded with PTX were conjugated to Tf 
(PTX–NPs–Tf) using an epoxy compound (Denacol-EX-521) [84]. These PTX–NPs–Tf 
showed a 70% in vitro inhibition of proliferation in human prostate cancer PC3 cells, while 
at the same concentration the NPs without ligand exhibited 25% inhibition, and PTX in 
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solution resulted in a 35% [84]. Tf-conjugated lipid-coated PLGA NPs carrying the 
aromatase inhibitor, 7α-(4´-amino)phenylthio-1,4-androstadiene-3,17-dione (7α-APTADD), 
were synthesized and evaluated for aromatase inhibition efficiency in SKBR-3 breast cancer 
cells. PLGA NPs loaded with the 7α-APTADD were significantly more effective preventing 
proliferation of the human breast cancer cell line SK-BR-3 than non-targeted NPs. These 
results suggested that the aromatase inhibition activity of the Tf-NPs was enhanced relative 
to that of the non-targeted NPs, which was attributable to TfR mediated uptake [87] 
Gan and coworkers observed that Tf-conjugated poly(lactide)-D-α-tocopheryl polyethylene 
glycol succinate diblock copolymer NPs loaded with Dtxl could be more efficient eliciting 
cytotoxicity against C6 glioma cells than other nontargeted formulations [88]. 
Transferrin–PEG–adamantane (Tf-PEG-AD) conjugates synthesized for NP modification 
have been used to target malignant tumors including Ewing's sarcoma [89-90]. Thus, several 
Tf-NPs have been successfully entered into clinical trials. CALA-01 [91] is one of the first 
clinically successful transferrin-conjugated nanoparticulate system. This system consists of a 
duplex of synthetic nonchemically modified siRNA, which self-assembles to a cationic 
copolymer containing cyclodextrin, AD-PEG as a stabilizing agent, and AD-PEG-Tf as the 
targeting moiety. After administration, the nanocomplex provides siRNA protection from 
nucleases in the serum, minimizes erythrocyte aggregation, and reduces complement 
fixation. At the tumor site, the Tf binds to the tumor cell TfR, which leads to preferential 
uptake of the complex within the tumor cell. In the cell, the polymer unpacks from the small 
interfering RNA allowing it to interfere with RNA resulting in reduced tumor growth [92].  
Hydroxycamptothecin (HCPT)-loaded stealth niosomes(NS) modified with transferrin (Tf-
PEG-NS) were prepared with poly(methoxy-polyethylene glycol cyanoacrylate-co-hexadecyl 
cyanoacrylate) (MePEG-PHDCA) as surface modification material [93]. Tf-PEG-NS 
demonstrated the strongest cytotoxicity to three carcinomatous cell lines (KB, K562 and S180 
cells), the greatest intracellular uptake especially in nuclei, the highest drug concentration and 
largest area under the intratumoral HCPT concentration curve, as well as the most powerful 
anti-tumor activity compared with other niosomes. More reciently Tf modified stealth NPs (Tf-
PEG-NP) encapsulating PEG-HCPT conjugate were prepared and was studied the possibility 
of combination of the functions of passive and active targeting by Tf-PEG-NP, as well as 
sustained drug release in tumor by PEGylated drug for most efficient tumor targeting and 
anti-tumor effects enhancement. The advantages of such system included prolonging drug 
residence time in circulation and increasing EPR effect by the sterically stabilising action of 
PEG-PHDCA NPs, active targeting function of transferrin by transferring receptor-mediated 
endocytosis, and sustained releasing drug in tumor by PEGylation of the drug. The prepared 
Tf-PEG-NP showed more sustained in vitro release profile. The pharmacokinetic and 
biodistribution studies found that Tf-PEG-NP demonstrated the longest retention time in 
blood, the highest tumor accumulation, as well as the most powerful anti-tumor activity with 
the inhibition rate up to 93% against S180 tumor in mice [94]. 
A pH-sensitive dual-targeting drug carrier (G4-Dox-PEG-Tf-TMX) was synthesized with Tf 
conjugated on the exterior and Tamoxifen (TMX) in the interior of the fourth generation (G4) 
Poly(amido amine))(PAMAM) dendrimers for enhancing the blood brain barrier (BBB) [35]. 
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The pH-triggered Dox release was 32% at pH 4.5 and 6% at pH 7.4, indicating a comparatively 
fast drug release at weak acidic condition and stable state of the carrier at physiological 
environment. MDR proteins, such as P-glycoprotein (P-gp), MRP4 (ABCC4), and breast cancer 
resistance protein (BCRP), are over expressed on the BBB and glioma cells, thus causing the 
block of overcoming the BBB and low uptake of drugs by the tumor cells [95]. The in vitro 
assay of the drug transport across the BBB model showed that G4-Dox-PEG-Tf-TMX exhibited 
higher BBB transportation ability. The carrier was internalized into C6 glioma cells upon 
crossing the BBB model by the coactions of TfR-mediated endocytosis and the inhibition effect 
of TMX to the drug efflux transports. Moreover, it also displayed the in vitro accumulation of 
DOX in the avascular C6 glioma spheroids made the tumor volume effectively reduced. 
But, besides of its natural ligand, Tf, it have also been used other ligands conjugated to NPs. 
Thus, antibodies and antibody fragments against the TfR are common examples of receptor 
targets [72]. Among these are the mAbs A24 [96], Rat anti-murine TfR RI7 217 and YE1/9.9, 
Murine anti-human TfR Antibody HB21(also known as 5E9), Antibody 454A12, Antibody 
B3/25, Antibody OKT9, R17217 and OX26 mAb [95,97-99].  
For instance the R17217, a rat IgG2a antibody against the mouse TfR which binds to this 
receptor on mouse cells [99], and the OX26, a murine Ab to the rat TfR, which is used for the 
delivery of peptides across the BBB [100], have been used in NP systems. Hence, it has been 
developed human serum albumin (HSA) NPs to which Tf was coupled, and was evaluated 
the potential of these NPs to deliver drugs across the BBB and, in addition, the possibility of 
achieving similar results by the coupling of the above-mentioned mAbs against the TfR 
receptor to the NPs was investigated. The analgesic Loperamide was chosen as the model 
drug since it does not cross the BBB [101]. HSA NPs coupled to Tf or TfR-mAb are enabling 
a significant loperamide transport across the BBB into the brain. The loperamide-loaded, Tf- 
or TfR-mAb-coupled HSA NPs achieved strong antinociceptive effects, whereas IgG2a-
modified HSA NPs were not able to transport this drug across the BBB [80]. Therefore, these 
novel NPs with attached Tf or TfR-mAb represent very useful carriers for the transport of 
drugs into the brain. It have also been used fluorescein labeled Chitosan (CS) nanospheres 
conjugated with PEG obtained with the PRINT (Particle Replication In Non-wetting 
Templates) technology that were bioconjugated either with the OKT9 murine anti-human 
TfR antibody (NPs–OKT9) or with human Tf (NPs–hTf) [102]. In both cases greater than 80% 
uptake was observed in several human tumor cell lines (HeLa, Ramos, H460, SKOV-3, 
HepG2, and LNCaP) compared to bovine Tf conjugated NPs (NPs–bTf) or control IgG1 
(NPs–IgG1). The targeting efficiency was dependent on nanocarrier concentration, ligand 
density, dosing time, and level of cell surface receptor expression. For these cells a strong 
correlation was found between the viability and the amount of ligand (OKT-9 or hTf) that 
can be conjugated to the surface of the NPs, with lower cell viability associated with higher 
percentage of ligand conjugate, suggesting that the polyvalency of the moiety targeting TfR 
plays a role in the toxicity in some malignancies [102]. 
3.4. Folate receptor 
Folic acid (FA) or folate, a member of the B complex group of vitamins with small-molecular 
weight (441 Da), is required by eukaryotic cells as is an important co-factor in one-carbon 
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transfer reactions for biosynthesis of nucleotide bases (purines and pyrimidines) and plays a 
key role in DNA and RNA synthesis, epigenetic processes, cellular proliferation, and 
survival [103-104]. Since folic acid is required for essential cell function, the cargo attached 
the ligand is retained within an endocytic vesicle or released into the cytoplasm. FA 
conjugates have the ability to deliver a variety of drugs or imaging agents to pathological 
cells without causing harm to normal tissues. Furthermore FA targeting is an interesting 
approach for cancer therapy because it offers several advantages over the use of monoclonal 
antibodies. Thus, FA is known to be stable, inexpensive, non-toxic, non-immunogenic, easy 
to conjugate to carriers [105], and FA-conjugated drugs or NPs are rapidly internalized via 
receptor-mediated endocytosis. 
Distinct transporters mediate cellular FA uptake. Among them, the FA transporter named as 
the folate receptor (FR) [9]. Three FR isoforms (FR-α, FR-β and FR-γ) have been identified in 
human tissues and tumors. FA can be internalized in cells by a low-affinity (KD of 
approximately 1-5 μmol/l) membrane-spanning protein, which transports reduced FAs 
directly into the cytosol or it can be endocytosed by a high-affinity glycoprotein (KD of 
approximately 100 pmol/l). FR, often referred to as the high affinity folate-binding protein, is a 
38 kDa cell surface glycosyl-phophatidylinositol (GPI)-anchored glycopeptides that 
characteristically binds folic acid and transports it by a nonclassical endocytic mechanism 
[106]. The receptor-mediated uptake of FA conjugates proceeds through a series of distinct 
steps [107]. The process begins with the conjugate binding to FRs on the cell surface. The 
plasma membrane then invaginates and eventually forms a distinct intracellular compartment. 
The endocytic vesicles become acidified, and then lysozymes are activated allowing the FR to 
release the FA conjugates. The membrane-bound FRs recycle back to the cell surface, allowing 
them to mediate the delivery of additional FA conjugates. Concurrently, the FA conjugates 
released from FRs escape the endosome, resulting in drug deposition in the cytoplasm. 
Functional FRs are largely localized to the apical surfaces of polarized epithelia [105]. Normal 
tissues express insignificant level of FR-α and low level of FR-β (such as liver), and FR-γ is 
only found in haematopoietic cells. However, FR-α and FR-β are vastly overexpressed in 
many human tumors such as uterus, colon, lung, prostate, ovaries, mammary glands, nose, 
throat and brain [11,107-108] which makes it a rational target for drug delivery to tumor 
tissues. At the tumor site, FA has a very high affinity for tumor cell surface FR and the 
complex is rapidly internalized into tumor cells (3x105 FA molecules/h) [109]. Studies have 
shown a significant correlation between FR-α expression and the grade and differentiation 
status of the tumor, thus poorly differentiated and aggressive tumors express high levels of 
FR-α [110]. However, immunochemistry studies have shown the overexpression of FA 
receptors in normal tissues like placenta and kidneys [13]. 
A wide range of chemical conjugates of FA, antifolate drugs, and immunological agents 
have been used for developing therapeutic and imaging agents for various diseases. Thus, it 
is not surprising that FA targeted NPs have shown to be effective in a number of tumors. A 
range of polymers with an improved biocompatibility have been used for the development 
of FR-targeted NPs [11]. In a typical FR-targeted NP, the anticancer agent is encapsulated in 
a stabilizing polymer and the FA is conjugated on the surface of the polymer. PEG is often 
used as a polymer in a FR-targeted nanoparticulate system to enhance its circulation time 
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and also to improve the association of the targeted NP with the tumor cells [111]. The 
surface density and length of PEG chains should be optimal to maintain the system 
targeting and stealth properties [72]. The mole fraction of FA added to a NP system is also 
thought to affect the cytotoxic capability of the system. It is presumed that higher ligand 
content would give an enhanced targeting ability. However, when excessive FA molecules 
are present on the surface of the NPs, they can self-assemble to form dimers, trimers or 
tubular quartets, which cannot interact with FR (only one molecule of FA can bind to FR) 
[112]. FA-PEG-liposome loaded with Dox showed a 45-fold higher uptake in FR-rich KB 
cells compared to nontargeted liposomal-doxorubicin and 86-fold greater cytotoxicity. In 
mice bearing KB cell tumor xenografts, treatment with FA-targeted liposomal Dox produced 
a 31% inhibition of tumor growth [37].  
Similar to PEG, PLGA NPs can be coated with FA to target the FR to further enhance 
accumulation of these NPs into tumor cells [113]. Copolymeric nanohydrogels based on N-
isopropylacrylamide (NIPA), N-(pyridin-4-ylmethyl)acrylamide (NPAM) and tert-butyl-2-
acrylamidoethyl carbamate (2AAECM), as well as FA-conjugate copolymeric nanogels, were 
synthesized and evaluated for antitumor therapy by loading them with TMX and 5-FU. 
Nanohydrogels were assayed as TMX and 5-FU delivery systems in vitro. Cell culture 
experiments were performed using MCF7, T47D and HeLa cells which have different degrees 
of FR expression. FA-targeted nanohydrogels showed a larger uptake into T47D and HeLa 
cells due to the fact that these cells are FR-positive. Furthermore, TMX-loaded and 5-FU-
loaded nanohydrogels showed effective elimination of carcinoma cells [38]. Loaded with the 
same drugs, it have also been synthesized FA-conjugate poly[(p-nitrophenyl acrylate)-co-(N-
isopropylacrylamide)] systems. TMX and 5-FU-loaded folate-systems present effective 
elimination of both MCF7 and HeLa cellular lines, and the presence of folate in the particles 
enhances their internalization, especially in HeLa cells [114-115]. 
A natural polymer (poly(3-hydroxybutyrate-co-3-hydroxyhexanoate), PHBHHX) was used 
as a base matrix for the production of a novel nanotherapeutic including antineoplastic 
agent, etoposide and attached FA as a ligand on the NPs. In the cytotoxicity tests, etoposide 
loaded and folic acid attached PHBHHX NPs were observed as more effective on HeLa cells 
than etoposide loaded PHBHHX NPs without attached folic acid. Furthermore the 
cytotoxicity of folic acid conjugated PHBHHX NPs to cancer cells was found to be much 
higher than that of normal fibroblast cells, demonstrating that the FA conjugated NPs has 
the ability to selectively target to cancer cells [116].  
CS NPs have also been conjugated to FA to target contrast dye to tumor tissues. The 
mucoadhesive property of CS provides sustained interaction with the target cells and the 
FR-mediated uptake leads to an enhanced imaging effect [117]. The cytotoxic activity of CS 
NP conjugated to FA has also been explored to show a higher cellular cytotoxicity due to 
enhanced uptake by receptor-mediated endocytosis complemented with a depot effect, 
which leads to sustained drug release providing grater apoptosis and enhanced cell cycle 
arrest [118]. An alginate-complexed FA CS NP has been reported for photodynamic early 
detection of colorectal carcinoma. These NPs are readily engulfed by the cancer cells 
through FR-mediated endocytosis, furthermore an improved release in the cellular lysosome 
was observed when they are loaded with 5-aminolevulinic acid (5-ALA) [119]. 
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In other system, FA was coupled with HSA NPs through carbodiimide reaction resulting in 
the formation of HSA-NPs spheres. The cellular binding and uptake was studied in normal 
foreskin fibroblasts (HFF), human neuroblastoma cells UKF-NB3, and in rat glioblastoma 
cell lines. An inceased NP uptake was observed in cancer cells, but not in normal HFFs [9]. 
3.5. Integrin 
Integrins are heterodimeric cell-surface receptors that consist of α- and β-subunits, such as 
integrins αvβ3 and αvβ5, and which are barely detectable or entirely absent from normal 
blood vessels but are abundantly expressed on tumor-associated endothelial cells [120-121]. 
Furthermore the αvβ3 integrin is important in the calcium-dependent signaling pathway 
leading to endothelial cell migration [122]. Endothelial cells undergoing angiogenesis 
experience at least three cellular alterations, including an increase in proliferation, increase 
in locomotion, and endothelial cell interaction with the ECM. These alterations are directly 
related to the adhesion processes of the αvβ3 integrin [122]. Thus, integrins represent 
potential pharmacological targets for antiangiogenic therapy. Several antibodies and 
peptides capable of functionally blocking the αvβ3 and αvβ5 integrins have been 
demonstrated to inhibit neovascularization in tumor-bearing mice. The targeting scheme for 
the αvβ3 integrin has centered upon the three amino acid sequence RGD. An important 
characteristic of the αvβ3 integrin is that it is intrinsically associated with VEGFR-2 signaling. 
Upon αvβ3 integrin binding to the components that harbor the RGD sequence, there is an 
upregulation of VEGF signaling in cell cultures. By blocking αvβ3 integrin binding, there 
would be a reduction in VEGF signaling, proving the use of αvβ3 blocking agents for anti-
angiogenesis [120]. Targeting the αvβ3 integrin with an active targeting NP system increases 
the effectiveness of anti-angiogenic treatments by the downregulation of VEGF. 
Park and coworkers [123] reported the development of self-assembled hydrogel NPs 
capable of imbibing a peptide sequence that specifically binds to αvβ3 integrin. The authors 
observed that NPs made of hydrophobically modified CS could release the peptide in a 
sustained manner, and showed that they might be useful for monitoring or destroying 
angiogenic vessels. Peptides that contain RGD domains can preferentially bind cells in 
tumor microvasculature that express the αvβ3 integrin [13]. However, RGD sequences also 
act as adhesive molecules and can non-specifically bind tissues that also express its integrin 
complement. Integrin receptors are also expressed on the cell membrane of macrophages 
[124] and it is shown that RGD bioconjugates aggregate in spleen and liver tissues due to 
macrophage clearance [125]. 
Using an RGD-targeted stealth system, NPs carrying Dox were found to accumulate faster 
and in higher concentrations in the liver and the spleen [126]. The ligands are incorporated 
as RGD-PEG-lipid conjugates, which indicates their extension from the NP surface as a 
consequence of the brush-like state. A report showed that short peptide-targeted NPs 
exhibited lower cell-bindings abilities when higher mol% of PEG2000 was included into the 
formulation [127-128]. As a sufficient PEG coating is essential for avoiding recognition by 
the RES, ligands should be extended away from NP surfaces, to avoid shielding by the 
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polymer chains. Another study reported the targeting and imaging of MDA-MB-231 human 
breast cancer cells using RGD peptide-labeled Fluorescent silica NPs (FSiNPs). The FSiNPs 
exhibited high target binding to αvβ3 integrin receptor (ABIR)-positive MDA-MB-231 breast 
cancer cells in vitro [129].  
Peptide-labeled NPs may also be used for targeted gene silencing. A study shows that RGD-
CS-NP is a highly selective delivery system for siRNA with the potential for broad 
applications in human disease [130]. Binding of RGD-CS-NP with αvβ3 integrin and 
antitumor efficacy were examined, resulted in significant inhibition of tumor growth 
compared with controls. The targeted RGD non-peptide mimetic coupled to NPs were 
coupled to cDNA encoding ATPμ-Raf tagged with the FLAG epitope [131] and were proven 
to cause tumor regression in M21-L melanomas. Peptides harboring RGD sequences have 
also shown high efficiencies in targeting SLK tumor endothelial cells derived from Kaposi's 
sarcoma. A cyclic RGD pentapeptide was conjugated to the surface of Dox-loaded micelles 
at different densities. A higher density of RGD sequences led to a higher level of cellular 
internalization of the micelles over the range of RGD densities. A 30-fold enhancement in 
micelle internalization was achieved with 76% RGD-functionalized Dox-loaded micelles as 
compared to the non-targeted micelles [132]. 
There are studies with other ligands. Thus, integrin-targeted C16Y peptide-modified 
liposomes (C16Y-L) were prepared to enhance the intracellular uptake of drugs and genes 
specifically into tumor tissues [133]. The C16Y peptide is a 12-amino acid modified C16 
synthetic peptide (DFKLFAVYIKYR-GGC), which is derived from the laminin γ1 chain, and 
binds to integrins αvβ3 and α5β1 [134]. The cellular uptake of C16Y-L by both endothelial 
cells and cancer cells was higher than uptake of the un-labeled and scramble peptide-
modified liposomes. Moreover, to evaluate whether the uptake depended on an integrin–
ligand interaction, they examined the inhibition of C16Y-L uptake using recombinant 
integrin αvβ3 and found that the cellular uptake of C16Y-L treated with αvβ3 integrin 
decreased. This result suggests that C16Y-L can selectively target cells that highly express 
integrin αvβ3.  
Finally, a new strategy is to use a multi-targeting NP systems. For instance, PTX-loaded NPs 
based on Herein, an hyperbranched amphiphilic poly[(amine-ester)-co-(D,L-lactide)]/1,2-
dipalmitoyl-sn-glycero-3-phosphoethanolamine copolymer (HPAE-co-PLA/DPPE), which 
was modified with two targeting ligands, RGD and Tf were synthesized [135]. Thus, these 
dual-targeting NPs may achieve more accumulation and improved lethality of the PTX-
loaded NPs in tumors. Active tumors targeting can be achieved in two steps: the ligand 
RGD enhances the targeting migration and accumulation of NPs to the αvβ3 integrin-
expressing tumor vasculature and Tf then improves the cellular uptake of NPs by TfR-
expressing tumor cells. In addition, a heterobifunctional cross-linker, p-maleimidophenyl 
isocyanate (PMPI), used for hydroxyl to sulfhydryl coupling was introduced to the HPAE-
co-PLA/DPPE copolymer for the successful modification of targeting ligands [136-137]. 
Results showed the cytotoxicity and cellular uptake of PTX-loaded NPs against human 
cervical carcinoma (HeLa) cells for their tumor-targeting effects [135]. 
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4. Tumor cell targeting 
Cancer cells express different targets on their surface, some of them specific of each type of 
cancer. Active targeting of nanosystems for cancer treatment has been usually associated 
with a type of cancer and so with a specific target. 
While chemotherapy has been the standard of care for patients with different types of 
cancer, efforts have shifted toward evaluating novel targeted agents in an attempt to 
improve outcome. These targeted agents are directed towards key components in several 
signaling pathways. The potential of targeted therapies has stimulated the study of targeted 
nanocarriers that can allow synergistically act by binding and inhibiting cancer pathways 
while delivering therapeutic payloads. Tumor cell targeting involves many targets 
associated with the uncontrolled cell proliferation and the angiogenesis and others specifics 
for the different types of cancer (Table 2) 
 
CANCER TYPE TARGET AGENT REFERENCE 
Lung cancer 
(NSCLC) 
VEGFR 
Axitinib (Pfizer Inc., USA) [138] 
Cediranib (Recentin®, AstraZeneca plc, UK) [139] 
EGFR 
Cetuximab (Erbiux®, ImClone/Bristol-Myer 
Squibb, USA) 
[140] 
Erlotinib (Tarceva®, Genentech/Roche, 
Switzerland) 
[141] 
IGF-1R Figitumumab (CP-751871, Pfizer, USA) [142] 
Colorectal 
cancer 
VEGF-A 
Bevacizumab (Avastin®, Roche-Pharma AG, 
Germany) 
[143-145] 
EGFR 
Cetuximab (Erbiux®, ImClone/Bristol-Myer 
Squibb, USA) 
[146] 
Panitumumab (Amgen Inc; Thousand Oaks, 
USA) 
[147] 
Breast cancer 
HER2 
Transtuzumab (Herceptin®, Genentech) [148] 
Transtuzumab-DM1 (T-DM1; Genetech 
Inc/Roche) 
[149] 
Pertuzumab (Omnitarg®; Genentech/Roche) [150] 
PARP Olaparib (AZD2281; AstraZeneca) [151] 
Prostate cancer 
17-α-
hydroxylase
Abiraterone acetate (Zytiga, Cougar 
Biotechnology) 
[152] 
AR MDV3100 [153] 
EGFR 
Cetuximab (Erbiux®, ImClone/Bristol-Myer 
Squibb, USA) 
[154] 
HER2 Transtuzumab (Herceptin®, Genentech) [155] 
HER3 MM-121 (humanized antibody) [156] 
PSMA J591 (monoclonal antibody) [157] 
Table 2. Examples of targets for different types of cancer 
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4.1. Lung cancer 
Non-small cell lung cancer (NSCLC) involves signaling pathways that influence 
angiogenesis, tumorigenesis and tumor growth, and different targeted agents have been 
used towards vascular endothelial growth factor receptor (VEGFR), platelet-derived growth 
factor receptor (PDGFR), EGFR and insulin-like growth factor 1 receptor (IGF-1R) [158-159]. 
Furthermore, there is an increasing interest in using combinations of targeted agents to 
inhibit more than one pathway. 
Among agents that target VEGFR in the treatment of advanced NSCLC, axitinib [138] has 
resulted to be a potent selective inhibitor of these types of receptors; also cediranib [139] has 
been assayed in combination with carboplatin and PTX in the treatment of this kind of 
cancer. 
Over-expression of EGFR has been associated with angiogenesis and poor prognosis in 
NSCLC [160]. Cetuximab (Erbiux®, ImClone/Bristol-Myer Squibb, USA) is a chimeric mAb 
that targets the EGFR pathway by binding to the extracellular domain of the receptor and in 
this way inhibiting the receptor-associated tyrosine kinase (TK) activity [140]. Furthermore, 
inhibitors of TK activity of EGFR have been used for targeting the receptor pathway. Small-
molecule, such as erlotinib (Tarceva®, Genentech/Roche, Switzerland) and gefitinib 
(Iressa®, AstraZeneca plc, UK), compete reversibly with ATP to bind to the intracellular 
catalytic domain of EGFR TK and, thus, inhibit EGFR autophosphorylation and downstream 
signaling [161]. 
IGF-1R is a key signaling pathway that leads to the growth and survival of tumor cells [162] 
and is commonly overexpressed in lung cancer cells. Figitumumab (CP-751,871, Pfizer, 
USA) is a fully human monoclonal antibody that is a specific and potent inhibitor of IGF-1R. 
In combination with carboplatin/PTX, figitumumab has shown to be a promising antitumor 
agent as first line treatment of NSCLC [142]. Several other anti-IGF-1R mAbs are being 
investigated in the treatment of advanced NSCLC, among them IMC-A12 (cixutumumab; 
fully human IgG1 monoclonal antibody), MK0646 (dalotizumab; a humanized IgG1 
monoclonal antibody) and R1507 (fully humanized monoclonal antibody) [163]. 
Lung cancer is a heterogeneous disease with multiple mutations, and it is unlikely that any 
single signaling pathway drives the oncogenic behaviour of all tumors. In fact, multilevel 
cross-stimulation among the targets of the new biological agents can contribute to the 
relative failure of some target therapies. In this way, combining targeted therapies is a 
promising research approach to the treatment of NSCL, and an exhaustive review has been 
recently published by Custodio and coworkers [163] 
4.2. Colorectal cancer 
The systemic treatment of metastatic colorectal cancer (mCRC) involves the use of active 
cytotoxic drugs and biological agents either in combination or as single agents. 
Initial chemotherapy of mCRC is based on using several cytotoxic regimens [164]. These 
clinical trials are based on the results of key phase III studies conducted over the past 
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decade. The IFL regimen [irinotecan (I), 5-FU and leucovorin (LV)] has been extensively 
used [143]. Furthermore, combination of oxaliplatin and 5-FU/LV (FOLFOX4) [165] has 
improved the overall survival of mCRC patients. 
A significant percentage of patients with CRC receive a biological agent targeting the 
vascular endothelial growth factor A (VEGF-A) or EGFR over their treatment course. The 
currently available anti-VEGF-A agent is bevacizumab (Avastin®, Roche-Pharma AG, 
Germany), a humanized mAb. Different key clinical trials incorporating bevacizumab have 
been carried out. In the AVF2107 trial [144] the combination of IFL and bevacizumab 
improved the progression-free survival and the overall survival. The trial of bevacizumab 
plus oxaliplatin-based chemotherapy (FOLFOX4) or plus capecitabine/oxaliplation (XELOX) 
[143,145] showed a significantly increase in the progression-free survival, mainly with 
XELOX. 
The anti-EGFR mAbs indicated for mCRC treatment are cetuximab (Erbiux®, 
ImClone/Bristol-Myer Squibb, USA; a chimeric monoclonal antibody) and panitumumab 
(Amgen Inc; Thousand Oaks, USA; a fully human monoclonal antibody). Both of them are 
efficacy in the treatment of patients whose mCRC tumors express wild-type KRAS. Different 
clinical trials combining anti-EGFR agents and chemotherapy have been carried out. Thus, 
mCRC therapy (wild-type KRAS patients) based on cetuximab and FOLFIRY (CRYSTAL 
trial) [146] showed a significantly improved progression-free survival and overall survival. 
In a similar way, the combination of panitumumab and FOLFOX4 (PRIME trial) had a very 
positive impact on survival parameters in wild-type KRAS patients [147]. 
4.3. Breast cancer 
Breast cancer is the most common cancer affecting females and one of the main causes of 
mortality of women. This disease shows a high heterogeneous nature in terms of genetic 
features, molecular profiles and clinical behaviour. The high mortality caused by breast 
cancer can be attributed to the development of metastatic breast cancer [166]. The discovery 
of “genetic signatures” in breast cancers can provide key insights into the mechanisms 
underlying tumorigenesis and can be proven useful for the design of targeted therapeutic 
approaches [167-168].  
The HER2 is over-expressed 15-30% of invasive breast carcinomas [167]. Extracellular 
domain of HER2 has been the target of several monoclonal antibodies created in order to 
inhibit the proliferation of human cancer cells. Transtuzumab, a recombinant humanized 
anti-HER2 monoclonal antibody was approved by the FDA for immunotherapy of women 
with metastatic HER2 over-expressing breast carcinoma. This antibody provokes cell cycle 
arrest during G1 phase [148]. Transtuzumab has been extensively used to target different 
drug-loaded nanocarriers to breast cancer cells [169-170].  
Many hormone receptor positive breast cancers are resistant to hormone therapies. Thus, 
clinical trials have been developed combining therapies with biological and targeted agents 
(anti EGFR and HER2) for the treatment of estrogen receptor (ER) positive breast cancer. 
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Combination of geftinib, an EGFR TK inhibitor, with anastrozole [171] or TMX [172] has 
conducted to a light prolongation of progression-free survival of patients. Clinical trials 
based on combination of transtuzumab and letrozole (Femara), an oral non-steroidal 
aromatase inhibitor for the treatment of hormonally-responsive breast cancer, in patients 
with ER+/HER2+ metastatic breast cancer have demonstrated clinical benefit [173]. A large 
proportion of HER2+ cancers have developed resistance to HER2-targeted therapeutics, 
including resistance of tumor cells to trastuzumab. Several agents have been developed to 
overcome resistance to this monoclonal antibody. The conjugation of maytansinoid DM1 
with transtuzumab has generated transtuzumab-DM1 (T-DM1; Genetech Inc/Roche), that is 
active on HER2 overexpressing breast cancer and also transtuzumab-refractory tumors 
[149]. Another innovative targeted agent, which belongs, to the class of HER2-dimerization 
inhibitors, is pertuzumab (Omnitarg; Genentech/Roche), a recombinant humanized 
monoclonal antibody. Pertuzumab is directed against the highly conserved dimerization 
domain of HER2 [150]. The efficacy of adding pertuzumab to trastuzumab plus Dtxl for the 
first-line treatment of HER2-positive metastatic breast cancer was demonstrated in the 
randomized, double-blind, multinational, phase III CLEOPATRA trial [174]. 
Basal like breast cancers are the result of specific mutations. DNA lesions such as single-
stand breaks (SSBs) and double-strand breaks (DSBs) are common in the normal cellular 
metabolism, and can be repaired by specific DNA repair mechanisms. In one of these DNA 
repair mechanisms, poly-(adenosine diphosphate ribose) polymerase 1 (PARP1) is an 
important key of the pathway. PARP1-inhibitors (PARP1-I) have been developed for the 
treatment of advanced breast cancer. Olaparib (AZD2281; AstraZeneca)), a PARP1-I has 
been evaluated in BRCA (a tumor suppressor protein) mutated patients [151]. Also iniparib 
(BSI 201; 4-iodo-3-nitrobenzamide; Sanofi-Aventis), an irreversible PARP1-I, is under study 
in patients with metastatic triple-negative breast cancer [175]. However, studies carried our 
by Liu and coworkers [176] shown that Iniparib nonselectively modifies cysteine-containing 
proteins in tumor cells, and the primary mechanism of action for iniparib is likely not via 
inhibition of PARP activity. 
4.4. Prostate cancer 
The current standard treatment of localized prostate cancer consists of prostatectomy and 
radiation therapy, sometimes supplemented with hormonal therapies to prevent 
testosterone production, which include anti-androgens and luteinizing hormone-releasing 
hormone (LH-RH) agonists. In locally advanced or widespread prostate cancer, the disease 
gradually transforms to a metastatic hormone-refractory state. Despite castrate levels of 
testosterone, the tumor will finally become independent of androgens resulting in death 
within a few years from diagnosis. In fact, the mortality rate of metastatic prostate cancer is 
extremely high. Thus, novel therapies [177-178] are on demand for the treatment of the 
malignant forms of prostate cancer that recur after initial therapies, including hormone 
refractory (HRPC) and castration resistant prostate cancer (CRCP). 
Different molecules have been assayed as androgen and androgen receptor inhibitors. In 
this way, abiraterone acetate (Zytiga, Cougar Biotechnology) in combination with 
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prednisone has been recently approved by FDA for the treatment of CRCP in men who have 
received prior Dtxl chemotherapy [152]. Arbiraterone inhibits 17-α-hydroxylase, an enzyme 
of the testosterone biosynthesis pathway, decreasing circulating levels of the hormone. This 
enzyme is expressed in testicular, adrenal and prostate tumors. Regarding of androgen 
receptor inhibitors (AR-I), MDV3100 is an oral androgen receptor antagonist [153], which 
irreversibly binds to this intracellular receptor and causes no transcription of the gen.  
The EGFR family (EGFR/HER) receptors have long been implicated in prostate cancer 
initiation and progression. EGFR is overexpressed in 18-37% prostate cancers [179], and a 
direct correlation of HER2 overexpression with the risk of death and recurrence in prostate 
cancer has been reported [180]. Thus, monoclonal antibodies have been studied as treatment 
options for prostate cancer. The efficacy of combining cetuximab with mitoxantrone plus 
prednisolone have been analyzed in a phase II clinical trial in men with CRCP after 
receiving Dtxl, but the time to progression and overall survival did not improve with the 
addition of cetuximab [154]. In order to evaluate whether dual inhibition of EGFR and HER2 
would prolong the effectiveness of androgen withdrawal therapy (AWT) treatment in 
prostate cancer, studies using EGFR inhibitors (erlotinib and AG1478) and HER2 inhibitors 
(trastuzumab and AG879) were realized [155]. Results indicate that dual EGFR/HER2 
inhibition, administered together with AWT, sensitize prostate cancer cells to apoptosis 
during AWT. In general, studies using inhibitors of EGFR/HER1 and HER2 show that these 
molecules fared poorly in prostate cancer clinical trials. 
Recent research suggests that another family member HER3 (ErbB3) abets emergence of the 
castration resistant phenotype. The prostate cancer, in comparison to the normal tissue, 
overexpresses HER3 protein, which indicate poor prognosis. Antibody-based therapy that 
prevents ligand binding to ErbB3 appears promising and fully-humanized antibodies that 
inhibit ligand-induced phosphorylation of HER3 (ErbB3) are currently in early development 
[181]. HER3's signaling functions depend upon ligand binding to its extracellular domain 
and inhibitors are generated to disrupt this interaction. A recently-characterized, HER3-
specific humanized antibody MM-121 blocked ligand-dependent HER3 activation induced 
by the HER1, HER2 or MET receptors [156]. 
The IGF-R signaling pathway plays a role in prostate cancer. In fact, an increase risk of 
prostate cancer has been directly correlated with the circulating IGF-1 (one ligand of the 
IGF-R) levels [182]. An inhibitor de the IGF pathway is the anti-IGF-R mAb cixutumumab 
(IMC-A12; ImClone Systems), which was effective in both androgen-dependent and 
androgen-independent human prostate cancer in animal models [183]. 
PSMA has been identified as an ideal antigenic target in prostate cancer. PSMA is the most 
well-established, highly restricted prostate cancer cell surface antigen. It is expressed at high 
density on the cell membrane of all prostate cancers, and after antibody binding, the PSMA-
antibody complex is rapidly internalized along with any payload carried by the antibody. 
J591 is the first IgG mAb developed to target the extracellular domain of PSMA, and it has 
been deimmunized (humanized) to allow repeated dosing in patients. Three phase I studies 
have been carried out, two using the β-emitting radiometals yttrium 90 and lutetium 177 
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(177Lu), and a third using a cytotoxin (DM1) linked to J591 [157]. A phase II clinical trial 
(NCT00859781) to test the effectiveness of the radiolabel monoclonal antibody, 177Lu-J591 in 
combination with ketoconazole and hydrocortisone against prostate cancer is in progress. 
5. Conclusion 
The development of drug delivery systems that are able to modify the biodistribution, tissue 
uptake and pharmacokinetics of therapeutic agents is considered of great importance in 
biomedical research. Controlled release in drug delivery can significantly enhance the 
therapeutic effect of a drug. Among drug delivery systems, nanocarriers are the smallest 
devices for transport of drugs, and they comprises a variety of the type of nanoparticles 
developed for cancer, including liposomes, nanoshells, nanocapsules, dendrimers, polymer-
drug conjugates, polymeric nanogels and micelles, and polynucleotide nanoparticles. The 
attractive properties of nanomedicines include their ability of controlled release of drugs, 
the targeting of specific tissues and the biocompatibility. Because of their size, nanocarriers 
can be taken up, in many cases, very efficiently by cells, internalized and stored into 
cytoplasm or different organelles. Nanocarrier uptake into a cell depends on the cell-type, 
since some cells are more susceptible to include nonfunctionalized systems via their design. 
The unique attributes of tumors support extravasation of polymeric nanomedicines through 
large pores on the endotheliallayer and via the disordered neoplastic tissue architecture. 
Thus, nanoparticles target the tumor passively via the EPR effect if their size is smaller than 
100nm. Therefore, current research involves novel strategies to attach targeting ligands with 
high affinity for receptors overexpressed on tumors or ways to utilize the tumor´s own 
microenvironment as a stimulus for drug release. An active targeting strategy can improve 
the efficacy of the therapy and diminish side effects associated with drugs, since not all 
nanocarriers can overcome the cell membrane barrier without a targeting motif. 
Nanoparticle systems are able to target various portions of the tumor using specific 
targeting moieties and evade the problems associated with multi-drug resistance. Thus, to 
increase the delivery of a given drug to a specific target site, targeting ligands are 
conjugated to carriers. The presence of reactive pendant groups in nanogels make easy their 
vectorization forward specific cell motif by binding of ligands. Furthermore, it is an 
important fact that targeting ligands lead to macrophage recognition and faster clearance 
compared to the non-targeted nanoparticles. Various molecules, that include folates, 
transferrin, antibody and antibody fragments, peptides, aptamers, small molecules, and 
carbohydrates, have been used to target nanocarriers to specific receptors on tumoral cell 
surfaces. In many cases, ligand-targeted nanoparticles demonstrate better internalization by 
cancer cells and more effective intracellular drug delivery than other preparatios. The search 
for more molecular targets will advance the ability to improve delivery at the tumor level 
while decreasing toxicity to normal tissue. As a result, moieties-targeted drug-loaded 
nanoparticles, searching for new tumor targets, novel ligands, new strategies for targeting, 
and particle stabilization, are generally considered as promising candidates for cancer 
chemotherapy and we can expect their extensive clinical evaluation in the near future.  
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Nomenclature 
2AAECM: tert-butyl-2-acrylamidoethyl carbamate  
5-ALA: 5-aminolevulinic acid  
5-FU: 5-Fluorouracil  
7α-APTADD: 7α-(4´-amino)phenylthio-1,4-androstadiene-3,17-dione ) 
ABIR: αvβ3 integrin receptor  
AD: adamantane  
Apt: aptamer 
AR-I: androgen receptor inhibitor 
AWT: androgen withdrawal therapy  
BBB: blood brain barrier  
BCRP: breast cancer resistance protein  
CEM: leukemic lymphoid cells 
CRCP: castration resistant prostate cancer  
CS: Chitosan  
Dox: doxorubicin  
DSBs: double-strand breaks 
Dtxl: Docetaxel  
ECM: extracellular matrix 
EGF: epidermal growth factor  
EGFR (or HER1): epidermal growth factor receptor 1 
EPR: Enhanced Permeability and Retention 
ER: estrogen receptor  
EU: European Union 
FA: Folic acid or folate 
FDA: Food and Drug Administration 
FR: folate receptor  
FSiNPs: Fluorescent silica nanoparticles 
GPI: glycosyl-phophatidylinositol  
HB-EGF: heparin-binding epidermal growth factor 
HCPT: Hydroxycamptothecin  
HER: Human epidermal receptor  
HER2: epidermal growth factor receptor 2 
HER3: epidermal growth factor receptor 3 
HFF: Human foreskin fibroblasts 
HNSCC: Head and neck squamous cell carcinoma 
HPAE-co-PLA/DPPE: hyperbranched amphiphilic poly[(amine-ester)-co-(D,L-lactide)]/1,2-
dipalmitoyl-sn-glycero-3-phosphoethanolamine copolymer  
HRPC: hormone refractory prostate cancer 
HSA: human serum albumin  
I: irinotecan 
IFL regimen: irinotecan + 5-FU + leucovorin  
IFP: interstitial fluid pressure 
IGF: insulin-like growth factor  
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IGF-1R: insulin-like growth factor 1 receptor  
LH-RH: luteinizing hormone-releasing hormone  
LV: leucovorin 
mAb: monoclonal antibody 
MAPK: mitogen-activated protein kinases  
mCRC: metastatic colorectal cancer  
MePEG-PHDCA: poly(methoxy-polyethylene glycol cyanoacrylate-co-hexadecyl cyanoacrylate)  
MTX: Methotrexate 
MUC1: mucin 1 
NCs: nanoclusters  
NIPA: N-isopropylacrylamide  
NPAM: N-(pyridin-4-ylmethyl)acrylamide  
NPs: nanoparticles 
NRs: nanorods 
NS: niosomes 
NSCLC: Non-small cell lung cancer 
PAMAM: Poly(amido amine) 
PARP1: poly-(adenosine diphosphate ribose) polymerase 1 
PARP1-I: poly-(adenosine diphosphate ribose) polymerase 1 -inhibitors 
PDGFR: platelet-derived growth factor receptor 
PEG: polyethylene glycol 
P-gp: P-glycoprotein  
PHBHHX: poly(3-hydroxybutyrate-co-3-hydroxyhexanoate) 
PLGA: poly(D,L-lactide-coglycolyde)  
PMPI: p-maleimidophenyl isocyanate 
PRINT technology: Particle Replication In Non-wetting Templates technology 
PSMA: Prostate-specific membrane antigen  
PTK7: protein tyrosine kinase-7  
PTX: Paclitaxel 
RES: reticuloendothelial system 
RGD: tripeptide arginine–glycine–aspartic acid  
SELEX: Systematic Evolution of Ligands by Exponential Enrichment  
siRNA: short inhibitory RNA  
SSBs: single-stand breaks  
SWNTs: single-wall carbon nanotubes  
Tf: Transferrin  
TfR: Transferrin receptor  
TGF-α: transforming growth factor-α  
TK: tyrosine kinase 
TLR9: Toll-like receptor 9  
TMX: Tamoxifen  
TNF: tumor necrosis factor  
VEGF: vascular endothelial grown factor 
VEGFR: vascular endothelial grown factor receptor 
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VPF: vascular permeability factor  
WHO: World Health Organization 
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